CITIUS ONCOLOGY, INC. 8-K

What Happened Citius Oncology, Inc. (CTOR) announced on April 29, 2026 that it has made the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners. The company filed an 8-K and attached a press release (Exhibit 99.1) to report the shipment.

Key Details

• Date of announcement: April 29, 2026.
• Product shipped: LYMPHIR™ (denileukin diftitox-cxdl).
• Market: Initial shipment to Europe.
• Distribution: Sent via one of Citius Oncology’s regional distribution partners (partner name not specified in the filing).

Why It Matters This 8-K confirms Citius Oncology is beginning commercial distribution activity for LYMPHIR in the European market, a tangible operational milestone that may affect future revenue recognition and market access. For investors, initial shipments can signal progress in commercialization and the start of potential sales reporting in upcoming financial periods, though the filing does not disclose sales volumes, timing of subsequent shipments, or financial terms.